Skip to content

Pilot Study to Validate ex Vivo Expression of Specific Biomarkers of Human Resolutive Macrophages

Pilot Study to Validate ex Vivo Expression of Specific Biomarkers of Human Resolutive Macrophages

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05106075
Acronym
RESOMACRO
Enrollment
20
Registered
2021-11-03
Start date
2021-07-07
Completion date
2024-01-07
Last updated
2021-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation

Keywords

macrophage, inflammation, inflammation resolution

Brief summary

Human resolutive macrophages are essential immune cells in the resolution of inflammation. This particular type of macrophages remains poorly known and currently there are no biomarkers to identify them in vivo. Within UMR1098-RIGHT, specific biomarkers (secreted molecules and membrane receptors) of human resolutive macrophages (healthy volunteers) have been identified in vitro, but their existence in vivo remains an outstanding issue. An exploratory study (lack of data from the literature) will validate the ex vivo expression of these markers in samples of patients whose inflammation is not, or little, supported by the available therapies (NSAIDs, biotherapies, corticosteroids).

Interventions

PROCEDUREblood sample or joint fluid or gingival exudate

blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Masking description

patients are anonymized

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age Limits (18-80 years) * Information and non-opposition for participating in the study * Patients suffering from periodontitis grade III ou IV * Patients suffering from microcristalline arthritis * patient with health insurance

Exclusion criteria

* patient under corticotherapy * pregnancy * non-compliant patient * patient with no health insurance * patient in exclusion period from an other study * legal incapacity

Design outcomes

Primary

MeasureTime frame
Quantification of cytokine concentrations in samples by ELISAup to 2 months

Countries

France

Contacts

Primary ContactThomas CHERRIER, MCU-PH
tcherrier@unistra.fr+33(0)768207057

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026